IKBKB and neoplasm: Nine doses of i.v administered IRF/IKKb PBAE complexes only displayed modest tumour progression, however when adjuvanted with radiotherapy as the standard of care for gliomas, the PBAE complexes group more than doubled the survival of treated mice compared to the control group (52 days compared to 25 days).